Uterine evacuation by vaginal misoprostol after second trimester pregnancy interruption

被引:13
作者
Bugalho, A
Bique, C
Pereira, C
Granja, AC
Bergstrom, S
机构
[1] UNIV OSLO,FAC MED,DEPT INT HLTH,N-0317 OSLO,NORWAY
[2] CENT HOSP,DEPT OBSTET & GYNAECOL,MAPUTO,MOZAMBIQUE
[3] UNIV UPPSALA HOSP,DEPT OBSTET & GYNAECOL,UPPSALA,SWEDEN
关键词
abortion; methylergometrine; misoprostol;
D O I
10.3109/00016349609047100
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background. The purpose was to study the capacity of vaginal misoprostol in combination with methylergometrine to achieve complete evacuation of the uterus without ensuing surgical evacuation of the uterine cavity. Methods. We performed this trial on 228 women seeking pregnancy interruption. Vaginal misoprostol was given in a dosage of 800 mu g in early second trimester. All women received concomitant treatment with peroral methylergometrine from the moment of misoprostol application every 8 hours until uterine evacuation. Follow-up was continued until the first menstruation after interruption. Results. Complete uterine evacuation was achieved in 173/228 cases (76%) [group 1]. The remaining 55 women [group 2] underwent manual evacuation of placental remnants trapped in the cervix. In seven of these women a conventional curettage was carried out due either to ultrasound evidence of placental remnants or due to uterine bleeding. The interval between misoprostol application and fetal expulsion averaged 14.9 hours (s.d. 9.6) in group 1 and 21.0 hours (s.d. 14.5) in group 2 (p=0.006). Conclusions. Misoprostol, in combination with methylergometrine, is a remarkably efficient drug in achieving uterine evacuation also in the absence of surgical evacuation of the uterine cavity. The present study provides justification for a more expectant attitude after vaginal misoprostol treatment for pregnancy interruption. The avoidance of close to 80% of otherwise conventional curettages would seem to represent a major advantage, particularly in settings where manpower and material resources are scarce. (C) Acta Obstet Gynecol Scand 1996
引用
收藏
页码:270 / 273
页数:4
相关论文
共 16 条
[1]  
ARILHA M, 1993, REPROD HEALTH MATTER, V2, P41
[2]   MISOPROSTOL, MIFEPRISTONE, AND ABORTION [J].
BAIRD, DT ;
NORMAN, JE ;
THONG, KJ ;
GLASIER, AF .
LANCET, 1992, 339 (8788) :313-313
[3]  
BUGALHO A, 1994, OBSTET GYNECOL, V83, P729
[4]   PREGNANCY INTERRUPTION BY VAGINAL MISOPROSTOL [J].
BUGALHO, A ;
BIQUE, C ;
ALMEIDA, L ;
BERGSTROM, S .
GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1993, 36 (04) :226-229
[5]  
BUGALHO A, 1995, GYNECOL OBSTET INVES, V74, P194
[6]  
BUGALHO A, 1995, ACTA OBSTET GYNECOL, V39, P252
[7]  
KOSTSONIS FN, 1985, DIG DIS SCI S11, V30, pS142
[8]  
MARGULIES M, 1991, PRENSA MED ARGENT, V78, P9
[9]   MISOPROSTOL TO INDUCE LABOR [J].
MARGULIES, M ;
PEREZ, GC ;
VOTO, LS .
LANCET, 1992, 339 (8784) :64-64
[10]   UTERINE CONTRACTILITY AND INDUCTION OF ABORTION IN EARLY-PREGNANCY BY MISOPROSTOL AND MIFEPRISTONE [J].
NORMAN, JE ;
THONG, KJ ;
BAIRD, DT .
LANCET, 1991, 338 (8777) :1233-1236